The inclusion of TERT promoter mutations within ctDNA for monitoring would increase the number of patients for whom ctDNA could be used to determine disease status, particularly amongst BRAF and NRAS wild-type melanoma patients. The gene discussed is BRAF; the disease is melanoma.